TransCode Therapeutics (RNAZ) Institutional Ownership $0.69 +0.00 (+0.07%) Closing price 04:00 PM EasternExtended Trading$0.69 0.00 (-0.03%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for TransCode Therapeutics (NASDAQ:RNAZ)Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$59.81MNumber ofInstitutional Sellers(last 12 months)0 Get RNAZ Insider Trade Alerts Want to know when executives and insiders are buying or selling TransCode Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RNAZ Institutional Buying and Selling by Quarter Remove Ads TransCode Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/1/2024 Sheets Smith Wealth Management50,138$29K0.0%+149.0%0.290% 5/20/2024 Virtu Financial LLC55,329$37K0.0%N/A0.836% 11/15/2023 Sabby Management LLC250,309$126K0.1%+32.8%12.330% 4/21/2022 K.J. Harrison & Partners Inc19,987$58K0.0%+24.9%0.155% 2/4/2022 Redmond Asset Management LLC88,010$224K0.1%N/A0.682% 1/26/2022 K.J. Harrison & Partners Inc16,000$41K0.0%N/A0.124% 11/16/2021ACT Capital L.L.C.50,000$150K0.1%N/A0.387% 11/16/2021 National Asset Management Inc.25,000$75K0.0%N/A0.194% 11/16/2021 Two Sigma Securities LLC33,314$100K0.0%N/A0.258% 11/12/2021 AIGH Capital Management LLC1,270,500$3.80M0.8%N/A9.845% (Data available from 1/1/2016 forward)Remove Ads RNAZ Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RNAZ shares? During the previous two years, the following institutional investors and hedge funds held shares of TransCode Therapeutics shares: Sabby Management LLC ($126K), and Virtu Financial LLC ($37K), Sheets Smith Wealth Management ($29K).Learn more on RNAZ's institutional investors. Which institutional investors have been buying TransCode Therapeutics stock? The following institutional investors have purchased TransCode Therapeutics stock in the last 24 months: Sabby Management LLC ($61.87K), Virtu Financial LLC ($55.33K), and Sheets Smith Wealth Management ($30K). How much institutional buying is happening at TransCode Therapeutics? Institutional investors have bought a total of 147,201 shares in the last 24 months. This purchase volume represents approximately $1.41B in transactions. Related Companies Cyclacel Pharmaceuticals Institutional Ownership Galera Therapeutics Institutional Ownership Vincerx Pharma Institutional Ownership ZyVersa Therapeutics Institutional Ownership Avenue Therapeutics Institutional Ownership Vaccinex Institutional Ownership Galmed Pharmaceuticals Institutional Ownership Salarius Pharmaceuticals Institutional Ownership Oncternal Therapeutics Institutional Ownership Eterna Therapeutics Institutional Ownership This page (NASDAQ:RNAZ) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.